Effector Therapeutics, Inc.

Jo Ann Z Wilson

Stephen Evan Webber

Siegfried Heinz Reich

Justin T Ernst

Alan X Xiang

Paul A Sprengeler

Bennett C Borer

Samuel Sperry

The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Crystalline forms of Mnk inhibitors

The present invention provides crystalline solids of 6'-((6-aminopyrimidin-4-yl)amino)-8&#x2032;-methyl-2&#x2032;H-spiro[cyclohexane-1,3&#x2032;-imidazo[1,5-a]pyridine]-1&#x2032;,5&#x2032;-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Crystalline forms of MNK inhibitors

Growing community of inventors

San Francisco, CA, United States of America

Jo Ann Z Wilson